Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 17.57%.

  • Puma Biotechnology's EBIT Margin fell 98400.0% to 17.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.83%, marking a year-over-year increase of 25300.0%. This contributed to the annual value of 13.44% for FY2024, which is 4200.0% down from last year.
  • Latest data reveals that Puma Biotechnology reported EBIT Margin of 17.57% as of Q3 2025, which was down 98400.0% from 12.66% recorded in Q2 2025.
  • Puma Biotechnology's EBIT Margin's 5-year high stood at 27.41% during Q3 2024, with a 5-year trough of 31.16% in Q2 2021.
  • Its 5-year average for EBIT Margin is 7.13%, with a median of 8.96% in 2023.
  • Per our database at Business Quant, Puma Biotechnology's EBIT Margin plummeted by -412600bps in 2021 and then soared by 514200bps in 2022.
  • Over the past 5 years, Puma Biotechnology's EBIT Margin (Quarter) stood at 0.91% in 2021, then skyrocketed by 1358bps to 11.43% in 2022, then soared by 79bps to 20.5% in 2023, then grew by 10bps to 22.62% in 2024, then decreased by -22bps to 17.57% in 2025.
  • Its EBIT Margin was 17.57% in Q3 2025, compared to 12.66% in Q2 2025 and 8.66% in Q1 2025.